Context Therapeutics Inc. (CNTX): Nasdaq/NYSE listing notice — Context Therapeutics receives Nasdaq minimum bid price deficiency notice

Context Therapeutics Inc.

Received Nasdaq deficiency notice on Feb 27, 2025 for failing $1.00 minimum bid price for 30 consecutive business days.
Initial 180-day cure period runs until August 26, 2025 to regain compliance.
Must have closing bid price of $1.00+ for at least 10 consecutive business days to cure.
Company will monitor and evaluate options, but no assurance of regaining compliance.
If not cured by Aug 26, may be eligible for an additional 180-day grace period.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Context Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 27, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. The Notification Letter provides an initial 180 calendar day period, or until Augu

View on SEC.gov

Browse all listing & compliance notices →

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-25-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.